BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17333516)

  • 1. Biosimilars: recent developments.
    Covic A; Kuhlmann MK
    Int Urol Nephrol; 2007; 39(1):261-6. PubMed ID: 17333516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars--global issues, national solutions.
    Knezevic I; Griffiths E
    Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are biosimilars really generics?
    Misra A
    Expert Opin Biol Ther; 2010 Apr; 10(4):489-94. PubMed ID: 20146636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biosimilar: can we manage biopharmaceutical heterogeneity?].
    Ranieri E
    G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues.
    Blandizzi C; Meroni PL; Lapadula G
    Clin Ther; 2017 May; 39(5):1026-1039. PubMed ID: 28416374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 12. Through the looking glass: the protein science of biosimilars.
    Goldsmith D; Kuhlmann M; Covic A
    Clin Exp Nephrol; 2007 Sep; 11(3):191-195. PubMed ID: 17891344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
    Combe C; Tredree RL; Schellekens H
    Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietins, biosimilars and immunogenicity.
    Schellekens H
    J Nephrol; 2008; 21(4):497-502. PubMed ID: 18651538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: controversies as illustrated by rhGH.
    Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
    Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory guidelines for biosimilars in Malaysia.
    Abas A
    Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars advancements: Moving on to the future.
    Tsuruta LR; Lopes dos Santos M; Moro AM
    Biotechnol Prog; 2015; 31(5):1139-49. PubMed ID: 25708573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.